Aureka Biotechnologies secures tens of millions in Series A to accelerate AI-driven antibody design and discovery

Recently, Aureka Biotechnologies, a biotechnology company focused on generative antibody drug development, announced the completion of a Series A funding round totaling tens of millions of US dollars. This round was jointly led by 5Y Capital and Qiming Venture Partners, with continued investment from existing shareholder NRL Capital and participation from other institutions such as Agentic Ventures.

The proceeds from this financing round will be utilized to advance the company's innovative drug pipeline into pivotal clinical stages, accelerate the build-out of its integrated wet-dry closed-loop AI Agent platform for antibody design, and foster in-depth collaborations with global biopharmaceutical enterprises.

Aureka Biotechnologies is fundamentally reshaping the paradigm for generating functional data by developing a self-evolving intelligent agent for antibody design. This agent is coupled with high-throughput single-cell functional screening and yeast intracellular automated directed evolution platforms. This integrated approach creates a high-throughput, high-content experimental data flywheel that continuously trains and refines the AI, resulting in a differentiated capability for antibody discovery and optimization. This enables us to efficiently build a pipeline of First-in-Class (FIC) and Best-in-Class (BIC) antibody therapeutics.

Aureka Biotechnologies is continuously enhancing the functional dimensions, phenotypic precision, and throughput of its data acquisition. This effort is focused on building a multi-dimensional, multi-objective AI Agent for antibody design capable of autonomous iteration. The platform is consistently expanding its generalization boundaries and directed optimization capabilities for complex targets, mechanisms, and indications. The company has strategically positioned itself in several high-value, high-challenge areas, including epitope-specific targeting antibodies, multi-specific antibodies, endocytosing antibodies, and pH-switch antibodies. This targeted approach enables the AI Agent to design molecules with enhanced safety and superior efficacy, ultimately yielding improved therapeutic outcomes and a clear differentiated clinical advantage.

In both technology validation and business collaboration, Aureka Biotechnologies has established substantive partnerships with several major pharmaceutical companies in Europe and the United States. These collaborations have centered on complex targets and functional mechanisms, establishing joint discovery programs that have consistently demonstrated the platform's significant advantages over traditional approaches in these high-value application scenarios.

Concurrently, the company is advancing multiple self-developed pipelines, focusing on therapeutic areas with high unmet needs such as autoimmune diseases and metabolic disorders. Several projects have entered the PCC or pre-IND critical stages.

Over the past two years, Aureka Biotechnologies has generated tens of millions of USD in commercial revenue and continues to expand opportunities for long-term pipeline co-development and collaborative partnerships.

Dr. Wei'an Zhao, Founder and CEO of Aureka Biotechnologies, stated, "We believe that therapeutic antibodies are not merely discovered but can be actively designed. Unleashing the full potential of an autonomous AI agent lies not in using it as an analytical aid, but in empowering it to make decisions, drive design, and guide experiments. By integrating it with our high-throughput experimental platforms, we achieve closed-loop iteration. Our vision is to build more than an algorithm—it is a world model for antibody design that continuously evolves and possesses genuine creative capability."